The 1998 domestic state of development of cognitive enhancers

Masaya Hasegawa, Yukihiro Noda, Yohko Maeda, Kiyofumi Yamada, Toshitaka Nabeshima

Research output: Contribution to journalReview article

Abstract

Recently, there is a great social problem that geriatric disorders, especially senile dementia, are growing rapidly with the increasing percentage of aged individuals in the total population. However, there is yet no drug that has reliable effects on senile dementia on the market. Therefore, society requires the development of new drugs that can support patients so that they can smoothly live their daily lives by themselves. In this study, we attempted to investigate the 1998 domestic state of development of cognitive enhancers by summarizing many publications and by gathering questionnaires from pharmaceutical, food, synthetic fiber and chemical manufacturing companies. There were 40 currently investigated cognitive enhancers in Japan as of the end of March, 1999 including 37 newly synthesized compounds and 3 new dosage forms or applications of additional effects. On the classification according to the mechanism of drug action, 12 of the investigated drugs are cholinomimetic agents, 12 are ameliorators of neuronal transmission, 1 is an intracellular mediative substance, 3 are neuropeptides, 2 are cerebral metabolic activators, 2 are cerebral circulation enhancers and 7 are neuronal cell protectors, and 1 is another type. For dementia of the Alzheimer's type, there are 1, 3, 10 and 2 drugs in prerecognition, phase late II, early II and I of clinical trials, respectively. For cerebrovascular dementia and cerebrovascular disease, there are 19 drugs being investigated. Seven of these compounds such as E2020 (donepedil HCl), DM-9384 (nefiracetam), TA-0910 (taltirelin), NS-3 (montirelin), TTC-909 (clinprost), DR-3305 (ebselen) and AVS (nicaraven) are at the prerecognition stage for marketing. It is important that effective cognitive enhancers will be supplied for clinical stage use as soon as possible.

Original languageEnglish
Pages (from-to)327-336
Number of pages10
JournalFolia Pharmacologica Japonica
Volume114
Issue number6
DOIs
Publication statusPublished - 01-01-1999
Externally publishedYes

Fingerprint

Nootropic Agents
montirelin
Pharmaceutical Preparations
Alzheimer Disease
TA 0910
TEI 9090
Cerebrovascular Circulation
Cerebrovascular Disorders
Social Problems
Dosage Forms
Marketing
Neuropeptides
Geriatrics
Cholinergic Agents
Dementia
Publications
Japan
Clinical Trials
Food

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Hasegawa, Masaya ; Noda, Yukihiro ; Maeda, Yohko ; Yamada, Kiyofumi ; Nabeshima, Toshitaka. / The 1998 domestic state of development of cognitive enhancers. In: Folia Pharmacologica Japonica. 1999 ; Vol. 114, No. 6. pp. 327-336.
@article{cf43926db6c449da8c8b2b731170575d,
title = "The 1998 domestic state of development of cognitive enhancers",
abstract = "Recently, there is a great social problem that geriatric disorders, especially senile dementia, are growing rapidly with the increasing percentage of aged individuals in the total population. However, there is yet no drug that has reliable effects on senile dementia on the market. Therefore, society requires the development of new drugs that can support patients so that they can smoothly live their daily lives by themselves. In this study, we attempted to investigate the 1998 domestic state of development of cognitive enhancers by summarizing many publications and by gathering questionnaires from pharmaceutical, food, synthetic fiber and chemical manufacturing companies. There were 40 currently investigated cognitive enhancers in Japan as of the end of March, 1999 including 37 newly synthesized compounds and 3 new dosage forms or applications of additional effects. On the classification according to the mechanism of drug action, 12 of the investigated drugs are cholinomimetic agents, 12 are ameliorators of neuronal transmission, 1 is an intracellular mediative substance, 3 are neuropeptides, 2 are cerebral metabolic activators, 2 are cerebral circulation enhancers and 7 are neuronal cell protectors, and 1 is another type. For dementia of the Alzheimer's type, there are 1, 3, 10 and 2 drugs in prerecognition, phase late II, early II and I of clinical trials, respectively. For cerebrovascular dementia and cerebrovascular disease, there are 19 drugs being investigated. Seven of these compounds such as E2020 (donepedil HCl), DM-9384 (nefiracetam), TA-0910 (taltirelin), NS-3 (montirelin), TTC-909 (clinprost), DR-3305 (ebselen) and AVS (nicaraven) are at the prerecognition stage for marketing. It is important that effective cognitive enhancers will be supplied for clinical stage use as soon as possible.",
author = "Masaya Hasegawa and Yukihiro Noda and Yohko Maeda and Kiyofumi Yamada and Toshitaka Nabeshima",
year = "1999",
month = "1",
day = "1",
doi = "10.1254/fpj.114.327",
language = "English",
volume = "114",
pages = "327--336",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "6",

}

The 1998 domestic state of development of cognitive enhancers. / Hasegawa, Masaya; Noda, Yukihiro; Maeda, Yohko; Yamada, Kiyofumi; Nabeshima, Toshitaka.

In: Folia Pharmacologica Japonica, Vol. 114, No. 6, 01.01.1999, p. 327-336.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The 1998 domestic state of development of cognitive enhancers

AU - Hasegawa, Masaya

AU - Noda, Yukihiro

AU - Maeda, Yohko

AU - Yamada, Kiyofumi

AU - Nabeshima, Toshitaka

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Recently, there is a great social problem that geriatric disorders, especially senile dementia, are growing rapidly with the increasing percentage of aged individuals in the total population. However, there is yet no drug that has reliable effects on senile dementia on the market. Therefore, society requires the development of new drugs that can support patients so that they can smoothly live their daily lives by themselves. In this study, we attempted to investigate the 1998 domestic state of development of cognitive enhancers by summarizing many publications and by gathering questionnaires from pharmaceutical, food, synthetic fiber and chemical manufacturing companies. There were 40 currently investigated cognitive enhancers in Japan as of the end of March, 1999 including 37 newly synthesized compounds and 3 new dosage forms or applications of additional effects. On the classification according to the mechanism of drug action, 12 of the investigated drugs are cholinomimetic agents, 12 are ameliorators of neuronal transmission, 1 is an intracellular mediative substance, 3 are neuropeptides, 2 are cerebral metabolic activators, 2 are cerebral circulation enhancers and 7 are neuronal cell protectors, and 1 is another type. For dementia of the Alzheimer's type, there are 1, 3, 10 and 2 drugs in prerecognition, phase late II, early II and I of clinical trials, respectively. For cerebrovascular dementia and cerebrovascular disease, there are 19 drugs being investigated. Seven of these compounds such as E2020 (donepedil HCl), DM-9384 (nefiracetam), TA-0910 (taltirelin), NS-3 (montirelin), TTC-909 (clinprost), DR-3305 (ebselen) and AVS (nicaraven) are at the prerecognition stage for marketing. It is important that effective cognitive enhancers will be supplied for clinical stage use as soon as possible.

AB - Recently, there is a great social problem that geriatric disorders, especially senile dementia, are growing rapidly with the increasing percentage of aged individuals in the total population. However, there is yet no drug that has reliable effects on senile dementia on the market. Therefore, society requires the development of new drugs that can support patients so that they can smoothly live their daily lives by themselves. In this study, we attempted to investigate the 1998 domestic state of development of cognitive enhancers by summarizing many publications and by gathering questionnaires from pharmaceutical, food, synthetic fiber and chemical manufacturing companies. There were 40 currently investigated cognitive enhancers in Japan as of the end of March, 1999 including 37 newly synthesized compounds and 3 new dosage forms or applications of additional effects. On the classification according to the mechanism of drug action, 12 of the investigated drugs are cholinomimetic agents, 12 are ameliorators of neuronal transmission, 1 is an intracellular mediative substance, 3 are neuropeptides, 2 are cerebral metabolic activators, 2 are cerebral circulation enhancers and 7 are neuronal cell protectors, and 1 is another type. For dementia of the Alzheimer's type, there are 1, 3, 10 and 2 drugs in prerecognition, phase late II, early II and I of clinical trials, respectively. For cerebrovascular dementia and cerebrovascular disease, there are 19 drugs being investigated. Seven of these compounds such as E2020 (donepedil HCl), DM-9384 (nefiracetam), TA-0910 (taltirelin), NS-3 (montirelin), TTC-909 (clinprost), DR-3305 (ebselen) and AVS (nicaraven) are at the prerecognition stage for marketing. It is important that effective cognitive enhancers will be supplied for clinical stage use as soon as possible.

UR - http://www.scopus.com/inward/record.url?scp=0033385220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033385220&partnerID=8YFLogxK

U2 - 10.1254/fpj.114.327

DO - 10.1254/fpj.114.327

M3 - Review article

C2 - 10672593

AN - SCOPUS:0033385220

VL - 114

SP - 327

EP - 336

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 6

ER -